John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Trump Says Anthropic No Longer Seen as National Security Threat 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
BOSTON, Feb. 03, 2016 -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biosimilar company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs), today announced that the Company is scheduled to participate in a fireside chat at the LEERINK Partners
5th Annual Global Healthcare Conference in New York City on Wednesday, February 10, 2016 at 11:30 a.m. ET.
The link to the live audio webcast and replay of the presentation may be accessed on the EPIRUS' website at http://ir.epirusbiopharma.com/events.cfm. The webcast will be archived on the Company's website for a period of three months.
About EPIRUS Biopharmaceuticals
EPIRUS Biopharmaceuticals (Nasdaq:EPRS) is a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs). EPIRUS' goal is to improve global patient access to important, cost-effective medicines. EPIRUS' current pipeline of biosimilar product candidates includes: BOW015 (infliximab, reference biologic Remicade®); BOW050 (adalimumab, reference biologic Humira®); BOW070 (tocilizumab, reference biologic Actemra®); BOW080 (eculizumab, reference biologic Soliris®); BOW090 (ustekinumab, reference biologic STELARA®); and BOW100 (golimumab, reference biologic SIMPONI®)ii. The reference products for these candidates together generated approximately $29.2 billion in global sales for 2014, according to EvaluatePharma®. EPIRUS has established multiple partnerships to support its regulatory and commercialization efforts in global markets. For more information visit EPIRUS' website at www.epirusbiopharma.com.
Contact Information: For media inquiries: Mike Devine, FleishmanHillard +1-212-453-2324 [email protected] For investor inquiries: Marek Ciszewski, J.D. EPIRUS Biopharmaceuticals +1-617-553-9716 [email protected]
